# Jean‐Jacques Grob

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jean-jacques-grob/

## Facts

| Field | Value |
| --- | --- |
| Citations | 81,657 |
| Field | Melanoma and MAPK Pathways |
| h-index | 106 |
| i10-index | 384 |
| Last Known Institution | Aix-Marseille Université |
| OpenAlex ID | https://openalex.org/A5061072132 |
| ORCID iD | https://orcid.org/0000-0002-0667-153X |
| Works | 1,007 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study](https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/)
- [Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016](https://scholariq.org/papers/diagnosis-and-treatment-of-melanoma-european-consensus-based-interdisciplinary/)
- [Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline](https://scholariq.org/papers/diagnosis-and-treatment-of-invasive-squamous-cell-carcinoma-of-the-skin-european/)
- [Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline](https://scholariq.org/papers/diagnosis-and-treatment-of-merkel-cell-carcinoma-european-consensus-based/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)
- [Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey](https://scholariq.org/papers/randomized-clinical-trials-for-psoriasis-1977-2000-the-eden-survey/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)

## Researcher university

- [Aix-Marseille Université](https://scholariq.org/institutions/aix-marseille-universite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.